Compare FLXS & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLXS | SWKH |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Diversified Financial Services |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.3M | 205.9M |
| IPO Year | N/A | 1999 |
| Metric | FLXS | SWKH |
|---|---|---|
| Price | $38.86 | $17.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 19.7K | 8.5K |
| Earning Date | 02-02-2026 | 03-18-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | 64.53 | ★ 120.89 |
| EPS | ★ 4.11 | 1.85 |
| Revenue | ★ $447,505,000.00 | $40,149,000.00 |
| Revenue This Year | $3.61 | $52.93 |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $9.37 | ★ $9.36 |
| Revenue Growth | 6.00 | ★ 62.38 |
| 52 Week Low | $29.38 | $13.17 |
| 52 Week High | $64.14 | $20.49 |
| Indicator | FLXS | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 51.16 |
| Support Level | $38.22 | $17.10 |
| Resistance Level | $42.42 | $17.60 |
| Average True Range (ATR) | 1.67 | 0.22 |
| MACD | -0.34 | -0.02 |
| Stochastic Oscillator | 13.10 | 47.17 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.